Drug intelligence / Profile preview

ZGN-839

Development stage: Discontinued
Lead developer: Larimar Therapeutics
Modality: Small Molecules

Overview

ZGN-839 is a liver-targeted small molecule inhibitor of methionine aminopeptidase 2 (MetAP2) developed by Zafgen for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity. MetAP2 inhibitors modulate cellular processes controlling metabolism by directing binding to stress mediators, thereby reducing lipid synthesis in the liver and promoting fat metabolism as an energy source. This mechanism aims to address underlying metabolic dysregulation in NASH without the systemic effects seen in earlier MetAP2 inhibitors like beloranib.[3]

Targets

METAP2 (Methionine aminopeptidase 2)

Beyond the preview

Go deeper on ZGN-839.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZGN-839.